Premium
Implications of oncocytic change in papillary thyroid cancer
Author(s) -
Hong Jun Hwa,
Yi HyonSeung,
Yi Shinae,
Kim HyeonWoo,
Lee Junguee,
Kim Koon Soon
Publication year - 2016
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.13115
Subject(s) - medicine , thyroid carcinoma , oncocytoma , endocrinology , thyroid cancer , gastroenterology , papillary thyroid cancer , thyroidectomy , pathology , cancer , thyroid , immunohistochemistry
Summary Objective Although the presence of oncocytic change in less than 75% of a tumour is not considered to indicate oncocytic variants of papillary thyroid carcinoma ( PTC ), we frequently observe partial oncocytic change, especially in obese PTC patients. Thus, we sought to investigate the relationship between the presence of oncocytic change of PTC and its prognosis. Design, setting and participants We retrospectively studied 142 patients with PTC who had undergone surgery between 2000 and 2005, and re‐evaluated their PTC slides to record the proportion of oncocytic change in 10% increments from 0% to 100%. Major outcome measure We analysed the relationship between the proportion of oncocytic change and clinicopathological prognostic factors. Results Oncocytic change was found in 45·8% (65/142) of PTC patients. The proportion of patients with oncocytic change was higher in obese patients than in lean patients and showed a significant correlation with the BMI ( r = 0·195, P = 0·020). The PTC patients with oncocytic change showed a higher recurrence rate than PTC patients without oncocytic change (30·8% vs 11·7%, respectively; P = 0·005). The presence of oncocytic change in PTC patients was associated with a shorter disease‐free survival in a Kaplan–Meier analysis after a mean follow‐up of 8·9 years. Conclusion The patients with PTC with oncocytic change presented with a higher recurrence rate and were more likely to be obese. These findings suggest that presence of oncocytic change is a poor prognostic factor in PTC patients, even if the oncocytic change involves less than 75% of a tumour.